| Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress |
LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). |
globenewswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript |
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Amanda Cray – Executive Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants James Shin – Deutsche Bank Matthew Phipps – William Blair Karina Rabayeva – Truist Gil Blum – Needham & Company Yanan Zhu – Wells Fargo Operator Good day, and thank you for standing by. Welcome to the Autolus First Quarter 2025 Financial Results Conference Call. |
seekingalpha.com |
2025-05-11 08:22:50 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates |
Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 million U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025 Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON, May 08, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the first quarter ended March 31, 2025. “We had a great first quarter of launch and are highly encouraged by physician enthusiasm for AUCATZYL in the U.S. We believe this speaks to the product profile and significant unmet need for patients,” said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1) |
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory |
globenewswire.com |
2025-04-25 16:06:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event |
Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) and multiple sclerosis (MS) Preliminary data in initial six patient cohort treated in Phase 1 trial in systemic lupus erythematosus (SLE) support progressing obe-cel into a planned Phase 2 pivotal study in lupus nephritis; first patient expected to be dosed in Phase 2 trial by year-end 2025 Company plans to advance obe-cel in progressive forms of multiple sclerosis (MS); first patient expected to be dosed in Phase 1 trial by year-end 2025 LONDON, April 23, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today presented updates on its development pipeline and plans for expansion in autoimmune diseases at an R&D investor event. The Company presented development plans to expand the obe-cel opportunity into autoimmune disease, including a potential registrational path for obe-cel in LN. |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 |
LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company's financial results and provide a general business update. |
globenewswire.com |
2025-04-22 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference |
LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST. |
globenewswire.com |
2025-04-02 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025 |
LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST. Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. |
globenewswire.com |
2025-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript |
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participants James Shin - Deutsche Bank Rajan Sharma - Goldman Sachs Asthika Goonewardene - Truist Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Yanan Zhu - Wells Fargo Jacob Mekhael - KBC Securities Simon Baker - Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to Discuss the Full Year 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded. |
seekingalpha.com |
2025-03-20 13:55:19 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates |
AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024 Obe-cel MHRA and EMA marketing authorizations expected in H2 2025 Initial six patients dosed in Phase 1 dose confirmation trial in Systemic Lupus Erythematosus (SLE) Company to provide clinical development program updates, including plans for expansion in autoimmune diseases, at R&D investor event to be held on April 23rd Conference call to be held today at 08:30 am EDT/12:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the full year ended December 31, 2024. “Reflecting on 2024, it was a year of strong execution leading to significant achievements for Autolus, including our strategic deal with BioNTech and corresponding financing to bolster our balance sheet, commencing GMP operations at our in-house CAR T manufacturing facility, and finishing the year with our first FDA approval and the commercial launch of AUCATZYL®,” said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2025-03-20 09:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 |
LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2024 financial results and operational highlights before open of US markets on Thursday, March 20, 2025. Management will host a conference call and webcast at 8:30 am EDT/12:30 pm GMT to discuss the company's financial results and provide a general business update. |
globenewswire.com |
2025-03-06 09:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Participate in Upcoming Investor Conferences |
LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. Jefferies Biotech on the Beach Summit Management to host investor meetingsDate: March 11, 2025Location: Miami, FL Leerink Global Biopharma Conference Fireside Chat PresentationDate and time: March 12, 2025; 8:40am EDT / 12:40pm GMTLocation: Miami, FLPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the fireside chat will be available on the “Events” page in the “Investor Relations & Media” section of the Company's website at https://www.autolus.com/investor-relations-media/events/. |
globenewswire.com |
2025-03-05 09:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy |
Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 years, alleviating immediate financial concerns. The company faces significant competition in the CD19 CAR T-cell therapy market, making sales execution crucial for success. |
seekingalpha.com |
2025-03-04 12:21:40 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings |
LONDON, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, being held from February 12-15, 2025, in Hawai'i Convention Center, Honolulu, HI. “Building on our data presented at ASH in December, we come to Tandem with an updated health economic cost model directly comparing the cost of adverse events of AUCATZYL® versus other CAR-T cell therapies, which demonstrates that the shorter duration and lower incidence of CRS and ICANS contributes to a reduction in healthcare costs,” said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2025-01-17 09:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 |
LONDON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces an oral presentation and three poster presentations at the American Society of Hematology (ASH) Annual Meeting, being held from December 7-10, 2024, in San Diego. “Our oral presentation at ASH this year with data from the FELIX trial demonstrates that obe-cel treatment produces a high incidence of deep molecular remission in r/r adult ALL patients, which correlates with better outcomes and is associated with longer event free survival (EFS) and overall survival (OS),” said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2024-12-09 21:30:00 |
Czytaj oryginał (ang.) |
| AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market |
Autolus Therapeutics' AUCATZYL, approved by the FDA for relapsed/refractory B-cell ALL, shows strong potential despite safety concerns. The Company's Obe-cel family and oncology pipeline include multiple catalysts for 2025, expanding potential indications in autoimmune diseases and hematologic malignancies. AUTL's cash runway of 1.9 years and no financial debt provide a solid financial foundation to support AUCATZYL's commercialization and future growth. |
seekingalpha.com |
2024-11-21 02:16:21 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics plc (AUTL) Q3 2024 Earnings Call Transcript |
Autolus Therapeutics plc (NASDAQ:AUTL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Olivia Manser - Director-Investor Relations Christian Itin - Chief Executive Officer Rob Dolski - Chief Financial Officer Conference Call Participants James Shin - Deutsche Bank Matthew Phipps - William Blair Sebastiaan van der Schoot - VLK Hanze Zu - Jefferies Gil Blum - Needham & Company Jacob Mekhael - KBC Securities Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Third Quarter 2024 Financial Results and Business Updates. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-12 16:57:37 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) |
AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) Approval based on FELIX clinical trial of obe-cel in adult patients with r/r B-ALL Conference call to be held on November 11 at 08:30 am EST/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the U.S. Food and Drug Administration (FDA) has granted marketing approval for AUCATZYL® (obecabtagene autoleucel) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). “Adult ALL is an extremely aggressive cancer, and there is a high unmet medical need that exists in the treatment of patients with this disease once they relapse, where historically they suffer from poor outcomes,” said Elias Jabbour, MD, U.S. lead investigator of the FELIX study and professor of Leukemia, ALL Section Chief, at The University of Texas MD Anderson Cancer Center, Houston, Texas. |
globenewswire.com |
2024-11-08 18:23:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 |
LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. |
globenewswire.com |
2024-10-28 19:00:00 |
Czytaj oryginał (ang.) |
| Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case |
Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, but now it has US and EU approval in its sights. |
seekingalpha.com |
2024-09-06 18:12:36 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics plc (AUTL) Q2 2024 Earnings Call Transcript |
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Olivia Manser – Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Asthika Goonewardene – Truist Kelly Shi – Jefferies James Shin – Deutsche Bank Matthew Phipps – William Blair Yanan Zhu – Wells Fargo Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Call to discuss its Second Quarter 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded. |
seekingalpha.com |
2024-08-10 04:05:28 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 |
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. |
globenewswire.com |
2024-07-26 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress |
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024. “We are looking forward to presenting longer-term data from adult patients with r/r ALL treated with obe-cel in the FELIX study,” said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2024-06-14 11:00:00 |
Czytaj oryginał (ang.) |
| Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget |
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality. |
investorplace.com |
2024-06-13 18:31:05 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO |
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated with improved event-free survival Autolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below) LONDON, May 31, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces longer-term follow-up and additional data analysis from the pivotal Phase 1b/2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). “At 21 months of median follow up, we're really pleased to be observing the potential for a long-term plateau of survival outcomes with obe-cel in the FELIX trial,” said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2024-05-31 12:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript |
Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2024 Earnings Conference Call May 17, 2024 8:30 AM ET Company Participants Olivia Manser – Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Kelly Shi – Jefferies James Shin – Deutsche Bank Asthika Goonewardene – Truist Matthew Phipps – Blair Gil Blum – Needham & Company Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics' Call to discuss its First Quarter 2024 Financial Results and Business Updates. As a reminder, this conference call is being recorded. |
seekingalpha.com |
2024-05-17 16:55:25 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates |
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (MAA) for obe-cel in r/r adult ALL accepted by European Medicines Agency (EMA) Conference call to be held today at 08:30 am EDT/13:30 pm BST: conference call participants should pre-register using the link at the bottom of this press release LONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces its operational and financial results for the first quarter ended March 31, 2024. “We continue to engage with the FDA in the regulatory review process for obecabtagene autoleucel (obe-cel) in adult ALL as we head towards the PDUFA target action date of November 16, 2024, and are driving commercial readiness activities across the Company," said Dr. Christian Itin, Chief Executive Officer of Autolus. |
globenewswire.com |
2024-05-17 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress |
LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024. Oral presentation: Title: obecabtagene autoleucel in adult relapsed/refractory B Cell acute lymphoblastic leukemia: Survival and potential impact of CAR-T cell persistence and stem cell transplantation in the FELIX study Session Title: s419 Acute lymphoblastic leukemia - Clinical 1: Immunotherapy: antibodies and CAR-T cells Session date and time: Friday, June 14 from 14:45 - 16:00 CEST Session room: N104 Final Abstract Code: S114 Presenting Author: Dr. Claire Roddie Poster presentations: Title: obecabtagene autoleucel (obe-cel, AUTO1) for relapsed/refractory adult B-Cell acute lymphoblastic leukemia (R/R B-ALL): The impact of inotuzumab-containing bridging therapy on treatment outcomes Session Title: Poster session Session date and time: Friday, June 14 from 18:00 - 19:00 CEST Final Abstract Code: P418 Presenting Author: Dr. Jae H. |
globenewswire.com |
2024-05-14 14:00:00 |
Czytaj oryginał (ang.) |
| Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO |
LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that the abstract for longer-term follow-up and additional data analysis from the pivotal Phase 2 FELIX study of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) was selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, (May 31 – June 4, 2024, Chicago). ASCO Oral Presentation, abstract #6504: Title: Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX Phase Ib/II study Session Title: Oral Abstract Session – Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Session date and time: Friday, May 31, 2024, 14:45 – 17:45 EDT, 19:45 – 22:45 BST Presenting Author: Dr Elias Jabbour, Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX A conference call and webcast to discuss the presented data will be held at 9:30 am EDT/2:30 pm BST on Saturday June 1, 2024. |
globenewswire.com |
2024-04-24 14:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 |
LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2024 financial results and operational highlights before open of US markets on Tuesday, May 14, 2024. Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. |
globenewswire.com |
2024-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Announces Changes to its Board of Directors |
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M.D., as Non-Executive Director. |
globenewswire.com |
2024-04-01 11:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript |
Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-15 07:23:07 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates |
Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million upfront, plus underwritten offering of ADSs for $350 million, for gross proceeds of $600 million received in February 2024 Submitted a Biologics License Application (BLA) for obecabtagene autoleucel (obe-cel), a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), to the US Food & Drug Administration (FDA); Prescription Drug User Fee Act (PDUFA) target action date November 16, 2024 Successfully completed first facility inspection and obtained a Manufacturer's Importation Authorization (MIA) from the Medicines and Healthcare products Regulatory Agency (MHRA), enabling the commercial product supply for obe-cel at The Nucleus manufacturing facility Submitted a Market Authorization Application (MAA) for obe-cel in r/r adult ALL with the European Medicines Agency (EMA) Conference call to be held today at 08:30 am EDT/12:30 pm GMT: Conference call participants should pre-register using the link at the bottom of this press release LONDON, March 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the full year ended December 31, 2023. “We're delighted to be starting 2024 in such a strong financial position; our recently announced strategic alliance with BioNTech, coupled with two equity financing transactions, raised gross proceeds of $600 million. |
globenewswire.com |
2024-03-14 09:00:00 |
Czytaj oryginał (ang.) |
| Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site |
LONDON, March 12, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that following the most recent GMP inspection by the MHRA in February 2024, Autolus' Nucleus manufacturing facility in Stevenage has obtained a Manufacturer's Importation Authorisation (MIA) together with the accompanying GMP certificate. This authorisation enables Autolus to manufacture for global commercial and clinical product supply from the Nucleus effective as of March 18, 2024. |
globenewswire.com |
2024-03-12 09:00:00 |
Czytaj oryginał (ang.) |